| Protein Name: | Parathyroid hormone (Q03431) |
|---|---|
| Gene Name: | PTHR1 |
| Description: | Parathyroid hormone/parathyroid hormone-related peptide receptor precursor (PTH/PTHr receptor) (PTH/PTHrP type I receptor) |
| PDB ID: | 1BL1 |
| Protein Family: | |
| Protein Category: | Membrane Receptors |
This panel provides drug-protein interaction and their ADRs along with references
| Interacting Drugs | Toxicity | Mechanism | Reference |
|---|---|---|---|
| Acetazolamide | Acidosis | Because parathyroid hormone@ 1@25-dihydroxyvitamin D and carbonic anhydrase are thought to be involved in bone buffering@the marked acidosis seen in haemodialysis patients treated with acetazolamide may be due to impaired parathyroid hormone-mediated bone buffering [ ADR Type 2 ] | Severe metabolic acidosis and disturbances of calcium metabolism induced by acetazolamide in patients on haemodialysis |
| Calcitriol | Acute Effects | Acute effects of intravenous 1 alpha-hydroxycholecalciferol on parathyroid hormone@ osteocalcin and calcitriol in man [ ADR Type 1 ] | Acute effects of intravenous 1 alpha-hydroxycholecalciferol on parathyroid hormone, osteocalcin and calcitriol in man |
| Dehydrated Alcohol | Hyperparathyroidism | The changes in parathyroid hormone are not consistent and since there is no greater incidence of hyperparathyroidism in alcoholic patients@ it SUGGESTS that alcohol does not have a long-term effect on the parathyroid glands. [ ADR Type 1 ] | Alcohol and bone disease Alcohol |
| Furosemide | Bone Demineralization | Four preterm infants receiving long-term furosemide therapy were examined for hypercalciuria@ hyperparathyroidism@ renal calcification@ and bone demineralization Three of them had high serum concentrations of parathyroid hormone [ ADR Type 2 ] | Secondary hyperparathyroidism and bone disease in infants receiving long-term furosemide therapy |
| Furosemide | Hypercalciuria | Four preterm infants receiving long-term furosemide therapy were examined for hypercalciuria@ hyperparathyroidism@ renal calcification@ and bone demineralization Three of them had high serum concentrations of parathyroid hormone [ ADR Type 2 ] | Secondary hyperparathyroidism and bone disease in infants receiving long-term furosemide therapy |
| Furosemide | Hyperparathyroidism | Four preterm infants receiving long-term furosemide therapy were examined for hypercalciuria@ hyperparathyroidism@ renal calcification@ and bone demineralization Three of them had high serum concentrations of parathyroid hormone [ ADR Type 2 ] | Secondary hyperparathyroidism and bone disease in infants receiving long-term furosemide therapy |
| Furosemide | Renal Calcification | Four preterm infants receiving long-term furosemide therapy were examined for hypercalciuria@ hyperparathyroidism@ renal calcification@ and bone demineralization Three of them had high serum concentrations of parathyroid hormone [ ADR Type 2 ] | Secondary hyperparathyroidism and bone disease in infants receiving long-term furosemide therapy |
| glucocorticoid | Osteoporosis | People also develop osteoporosis during glucocorticoid therapy and respond to dietary salt supplements by increasing urinary calcium excretion and parathyroid hormone [ ADR Type 1 ] | Effects of NaCl on calcium balance, parathyroid function and hydroxyproline excretion in prednisolone-treated rats consuming low calciumdiet |
| Paricalcitol | Adverse Oversuppression Of Pth | Paricalcitol increased serum calcium levels and decreased PTH and bone alkaline phosphatase levels (all P [ ADR Type 1 ] | A placebo-controlled trial to evaluate immunomodulatory effects of paricalcitol |
| Urea | Renal Failure | Patients with the highest urea percentiles showed significantly higher plasma levels of phosphorus and parathyroid hormone and significantly lower hemoglobin concentrations and bicarbonate levels@which lead to chronic renal failure [ ADR Type 2 ] | Urea percentiles in children with chronic renal failure Data from the ItalKid |
This panel provides information on drug category
| Toxicity | Source |
|---|